Single User License
INR 102030
Site License
INR 204060
Corporate User License
INR 306090

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


United Therapeutics Corporation-Product Pipeline Review-2015

United Therapeutics Corporation-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

United Therapeutics Corporation-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'United Therapeutics Corporation-Product Pipeline Review-2015', provides an overview of the United Therapeutics Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of United Therapeutics Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of United Therapeutics Corporation including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of United Therapeutics Corporation's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the United Therapeutics Corporation's pipeline products

Reasons To Buy

Evaluate United Therapeutics Corporation's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of United Therapeutics Corporation in its therapy areas of focus

Identify new drug targets and therapeutic classes in the United Therapeutics Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of United Therapeutics Corporation and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of United Therapeutics Corporation

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of United Therapeutics Corporation and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

United Therapeutics Corporation Snapshot 5

United Therapeutics Corporation Overview 5

Key Information 5

Key Facts 5

United Therapeutics Corporation-Research and Development Overview 6

Key Therapeutic Areas 6

United Therapeutics Corporation-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Pipeline Products-Partnered Products 10

Partnered Products/Combination Treatment Modalities 11

United Therapeutics Corporation-Pipeline Products Glance 12

United Therapeutics Corporation-Late Stage Pipeline Products 12

Pre-Registration Products/Combination Treatment Modalities 12

Phase III Products/Combination Treatment Modalities 13

United Therapeutics Corporation-Clinical Stage Pipeline Products 14

Phase I Products/Combination Treatment Modalities 14

United Therapeutics Corporation-Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

United Therapeutics Corporation-Drug Profiles 16

dinutuximab 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

beraprost sodium SR 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

PLX-PAD 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

UV-4B 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

esuberaprost sodium ER 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Human Antibody Based Vaccines 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Insulin Producing Islet Cells 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

Small Molecules for Viral Infections 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

United Therapeutics Corporation-Pipeline Analysis 31

United Therapeutics Corporation-Pipeline Products by Target 31

United Therapeutics Corporation-Pipeline Products by Route of Administration 32

United Therapeutics Corporation-Pipeline Products by Molecule Type 33

United Therapeutics Corporation-Pipeline Products by Mechanism of Action 34

United Therapeutics Corporation-Recent Pipeline Updates 35

United Therapeutics Corporation-Dormant Projects 39

United Therapeutics Corporation-Discontinued Pipeline Products 40

Discontinued Pipeline Product Profiles 40

8H-9 40

Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastom 40

UT-231B 40

United Therapeutics Corporation-Company Statement 41

United Therapeutics Corporation-Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

United Therapeutics Corporation, Key Information 5

United Therapeutics Corporation, Key Facts 5

United Therapeutics Corporation-Pipeline by Indication, 2015 7

United Therapeutics Corporation-Pipeline by Stage of Development, 2015 8

United Therapeutics Corporation-Monotherapy Products in Pipeline, 2015 9

United Therapeutics Corporation-Partnered Products in Pipeline, 2015 10

United Therapeutics Corporation-Partnered Products/ Combination Treatment Modalities, 2015 11

United Therapeutics Corporation-Pre-Registration, 2015 12

United Therapeutics Corporation-Phase III, 2015 13

United Therapeutics Corporation-Phase I, 2015 14

United Therapeutics Corporation-Preclinical, 2015 15

United Therapeutics Corporation-Pipeline by Target, 2015 31

United Therapeutics Corporation-Pipeline by Route of Administration, 2015 32

United Therapeutics Corporation-Pipeline by Molecule Type, 2015 33

United Therapeutics Corporation-Pipeline Products by Mechanism of Action, 2015 34

United Therapeutics Corporation-Recent Pipeline Updates, 2015 35

United Therapeutics Corporation-Dormant Developmental Projects,2015 39

United Therapeutics Corporation-Discontinued Pipeline Products, 2015 40

United Therapeutics Corporation, Other Locations 44

United Therapeutics Corporation, Subsidiaries 44

List of Figures

United Therapeutics Corporation-Pipeline by Top 10 Indication, 2015 7

United Therapeutics Corporation-Pipeline by Stage of Development, 2015 8

United Therapeutics Corporation-Monotherapy Products in Pipeline, 2015 9

United Therapeutics Corporation-Partnered Products in Pipeline, 2015 10

United Therapeutics Corporation-Pipeline by Top 10 Target, 2015 31

United Therapeutics Corporation-Pipeline by Top 10 Route of Administration, 2015 32

United Therapeutics Corporation-Pipeline by Top 10 Molecule Type, 2015 33

United Therapeutics Corporation-Pipeline Products by Top 10 Mechanism of Action, 2015 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of United Therapeutics Corporation; United Therapeutics Corporation - Key Therapeutics; United Therapeutics Corporation - Pipeline Overview and Promising Molecules; United Therapeutics Corporation - News; United Therapeutics Corporation - Latest Updates; United Therapeutics Corporation - Pipeline; United Therapeutics Corporation - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com